Causes of chronic diseases include a combination of genetics, smoking, exercise, poor eating habits, mutants in life such as constant stress, environmental causes such as environmental pollution, and changes in the physiological mechanism of the body. Chronic diseases such as heart disease, cancer, and stroke have contributed to modern death. Health psychologists have developed interventions that emphasize emotional management of people with chronic diseases. This includes helping people with chronic diseases follow prescribed treatments and maintain relationships with health care providers.
Chronic diseases are not easy to define in a word, but they are pathological conditions that last at least three months, and have the following characteristics: Once it occurs, it will take a long period of at least three months. It continues to improve and deteriorate, and eventually progresses in the direction of getting worse. Every time the deterioration is repeated, the pathological change increases and the return to physiological state decreases. Most chronic diseases increase with age, as the vocabulary means by regression. Most of the diseases in this disease group are rarely clearly attributed to infectious pathogens, except for several disease groups such as tuberculosis and leukemia. Severe chronic diseases go beyond the adaptation of the disease itself and cause a crisis in people’s lives. For example, it can cause financial difficulties, change the way patients see themselves, and affect family and friendship. First of all, the main effects of chronic diseases change people’s self-awareness. Diagnosis of diseases such as cancer changes people’s lives and goes through the process of understanding the meaning of their own diseases. And incorporates it into one’s life and perception. Negative emotions are common in chronic diseases. Thus, health psychologists have created interventions that emphasize emotional management of people with chronic diseases. This includes helping people with chronic diseases follow prescribed treatments and continue their relationship with health care providers. These conditions lead us to live with pain in our lives. However, based on much research and development, we would like to introduce a company that builds software-based systems for new drug R&D and produces significant results based on big data, hoping to escape from illness and free from pain. Several studies have already completed basic clinical trials with hospitals and have achieved great results, and I would like to briefly explain the company’s core in the following statements.
Based on KISDD (Knowledge-based In Silico Drug Discovery), a core technology of Ensol Biosciences in Korea established in 2001, it has established ETONS (Ensol Trans-Omics Network System), a “bio big data-based” software system that predicts toxic side effects of druggable candidates founded by KISDD. KISDD finds out all candidates for new drugs for incurable diseases with a “bio big data-based” hypothetical deductive search platform. Ensol’s drug pipelines that are mainly focused by KISDD technology cover new drugs for degenerative disk disease (DDD), osteoarthritis (OA), triple negative breast cancer (TNBC), Alzheimer’s disease (AD), and type 1 diabetes (T1D). The company’s strengths are seen as significantly reducing costs compared to existing drug discovery approaches and maximizing its potential with efficient access to clinical trials. Ensol Biosciences aims to create added value through new drug development, out-licensing , and new drug products. In addition to this, Ensol provides drug CMC (chemical, manufacturing, and control) services and CDMO (contract development and manufacturing organization) services .
Currently, access fields such as musculoskeletal diseases, anticancer drugs, central nervous system diseases, immune diseases, and animal medicines vary widely. It is expected to demonstrate the most appropriate approach to aging and longevity, which are of interest to the modern medical community.
As explained above, it is thought that global pharmaceuticals and bio companies should have interest and attention. It is said that it is preparing IND (Investigational New Drug) submission for clinical trials in U.S. to secure NDA (New Drug Approval) with the U.S. FDA for a more stable basis.
SAM KIM
Asia Journal
▲ Ensol Biosicences Inc.
▲ CEO : Hae-Jin Kim
▲ http://www.ensolbio.com
▲ info@ensolbio.com
▲ +82-42-939-4500
